Opposing effects of estrogen and progestins on LDL oxidation and vascular wall cytotoxicity: implications for atherogenesis.
Estrogens are widely regarded as beneficial to arterial wall health. Among the mechanisms of this benefit are antioxidant effects on LDL and the arterial wall. Because progestins oppose the effect of estrogen in several systems, we asked if progestins oppose the antioxidant effect of estrogen. To study this question, LDL and various female sex hormones were incubated alone and combined in the absence or presence of bovine aortic endothelial cells, placental trophoblast, or macrophages, and LDL oxidation and cytotoxicity were quantitated. In the absence of cells, LDL incubated with copper in phosphate-buffered saline enhanced the oxidation of LDL. When 17beta-estradiol was added to this system, an antioxidant effect was observed. Progestins inhibited this protective estrogenic effect. In endothelial cell culture, progestins also opposed the antioxidant effect of estrogen, with the strongest antiestrogenic effect seen with the synthetic progestins, levonorgestrel and medroxyprogesterone acetate (MPA). Endothelial cell cytotoxicity was proportional to the enhanced lipid peroxide formation observed with progestins or estrogen. Similar opposing effects were seen when estrogen and progesterone were added to primary cultures of placental trophoblast or macrophages. Thus, three cell culture systems modeling circulating arterial blood contact with cell surfaces demonstrated opposing effects of estrogens and progestins on LDL oxidation and cell cytotoxicity. These studies are in keeping with published reports that female sex steroids influence LDL oxidation in vivo and consequent arterial wall injury.
Zhu
X
X
Department of Medicine, Northwest Lipid Research Clinic, University of Washington, Seattle 98104, USA.
Bonet
B
B
Gillenwater
H
H
Knopp
R H
RH
D001161:Arteriosclerosis / Q000209:etiology*; D001808:Blood Vessels / Q000187:drug effects* / Q000473:pathology; D002470:Cell Survival / Q000187:drug effects; D004967:Estrogens / Q000494:pharmacology*; D008077:Lipoproteins, LDL / Q000378:metabolism*; D010084:Oxidation-Reduction; D011374:Progesterone / Q000494:pharmacology; D011372:Progestins / Q000494:pharmacology*
D004967:Estrogens; D008077:Lipoproteins, LDL; D011372:Progestins; C099252:oxidized low density lipoprotein; D011374:Progesterone